UBS/CALL/IDORSIA/16.001/0.1/21.06.24 | Market Closed - Swiss Exchange 11:20:00 2024-02-23 EST | ||
| 0.02 CHF | +100.00% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
IDORSIA LTD
Latest news about IDORSIA LTD
More news
Static data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | IDORSIA LTD |
| Issuer | UBS |
| FIDIFU | |
| ISIN | CH1170501832 |
| Date issued | 2022-06-19 |
| Strike | 16 CHF |
| Maturity | 2024-06-21 (37 Days) |
| Parity | 10 : 1 |
| Emission price | 0.44 CHF |
| Emission volume | N/A |
| Settlement | physical |
| Currency | CHF |
Technical Indicators
| Highest since issue | 0.56 CHF |
|---|---|
| Lowest since issue | 0.01 CHF |
Company Profile
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Sector
-
Consensus: Idorsia Ltd
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.346
CHF
Average target price
1.724
CHF
Spread / Average Target
-26.52%
- Stock Market
- Warrants
- FIDIFU Warrant